The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice

Journal of Applied Toxicology

Volumn 34, Issue 1, 2014, Pages 25-32

  Jesse, Cristiano R ^a   Bortolatto, Cristiani F ^b   Wilhelm, Ethel A ^b   Roman, Silvane Souza ^c   Prigol, Marina ^a   Nogueira, Cristina W ^b  

^a UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c DEPARTMENT OF FOOD ENGINEERING   (Brazil)

Author keywords

Cisplatin; Mice; Nephrotoxicity; Peroxisome proliferator activated receptor ; Pioglitazone

Indexed keywords

ASCORBIC ACID; BIOCHEMICAL MARKER; CATALASE; CISPLATIN; CREATININE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; PIOGLITAZONE; SUPEROXIDE DISMUTASE; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HISTOPATHOLOGY; KIDNEY PARENCHYMA; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; UREA BLOOD LEVEL;

MUS;

CISPLATIN; MICE; NEPHROTOXICITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ; PIOGLITAZONE;

ACUTE KIDNEY INJURY; ANIMALS; ASCORBIC ACID; CATALASE; CISPLATIN; CREATININE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INJECTIONS, INTRAPERITONEAL; KIDNEY; MALE; MICE; OXIDATIVE STRESS; PPAR GAMMA; PROTECTIVE AGENTS; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES;

EID: 84886781779     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2818     Document Type: Article

References (53)

1. Aebi, H. 1984. Catalase in vitro. Methods Enzymol. 105: 121-126.
2. Ajith TA, Usha S, Nivitha V. 2007. Ascorbic acid and a-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice, a comparative study. Clin. Chim. Acta 375: 82-86.
3. Ali BH, Al-Moundhri MS. 2006. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem. Toxicol. 44: 1173-1183.
4. Arany I, Safirstein RL. 2003. Cisplatin nephrotoxicity. Semin. Nephrol. 23: 460-464.
5. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A. 2005. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212: 116-123.
6. Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G. 2006. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J. Am. Soc. Nephrol. 17: 1624-1632.
7. Bonventre JV, Zuk A. 2004. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 66: 480-485.
8. Bradford, MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 72: 248-254.
9. Brandão R, Acker CI, Leite MR, Barbosa NBV, Nogueira CW. 2009. Diphenyl diselenide protects against glycerol-induced renal damage in rats. J. Appl. Toxicol. 29: 612-618.
10. Calberg I, Mannervik B. 1985. Glutathione reductase. Methods Enzymol. 113: 484-490.
11. Camargo SM, Francescato HD, Lavrador MA, Bianchi ML. 2001. Oral administration of sodium selenite minimizes cisplatin toxicitiy on proximal tubules of rats. Biol. Trace Elem. Res. 88: 251-262.
12. Casalino E, Sblano C, Landriscina V, Calzaretti G, Landriscina C. 2004. Rat liver glutathione S-transferase activity stimulation following acute cadmium or manganese intoxication. Toxicology 200: 29-38.
13. Chaudhry J, Ghosh NN, Roy K, Chandra R. 2007. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sci. 80: 1135-1142.
14. Colletti LM, Remick DG, Burtch GD. 1990. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J. Clin. Invest. 85: 1936-1943.
15. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. 2004. Pioglitazone prevents hypertension and reduces oxidative stress in dietinduced obesity. Hypertension 43: 48-56.
16. El Midaoui A, Wu L, Wang R, de Champlain J. 2006. Modulation of cardiac and aortic peroxisome proliferator-activated receptor gamma expression by oxidative stress in chronically glucose-fed rats. Am. J. Hypertens. 19: 407-412.
17. Fouad AA, Morsy MA, Gomaa W. 2008. Protective effect of carnosine against cisplatin-induced nephrotoxicity in mice. Environ. Toxicol. Pharmacol. 25: 292-297.
18. Gemba M, Fukuishi N. 1991. Amelioration by ascorbic acid of cisplatin induced injury in cultured renal epithelial cells. Contrib. Nephrol. 95: 138-142.
19. Giaccone G. 2000. Clinical perspectives on platinum resistance. Drugs 58: 9-4.
20. Habig WH, Palst MJ, Jakoby WB. 1974. Glutathione S-transferase. The first enzymatic step in mercapturic formation. J. Biol. Chem. 249: 7130-7139.
21. Hanigen MH, Devarajan P. 2003. Cisplatin nephrotoxicityt: molecular mechanisms. Cancer Ther. 1: 47-61.
22. Haraguchi G, Kosuge H, Maejima Y. 2008. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med. 34: 1304-1312.
23. Hissin PJ, Hilf R. 1976. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem. 74: 214-226.
24. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. 2005. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 288: C899-C905.
25. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50: 3-11.
26. Ito K, Shimada J, Kato D. 2004. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur. J. Cardiothorac. Surg. 25: 530.
27. Jacques-Silva MC, Nogueira CW, Broch LC, Flores EM, Rocha JBT. 2001. Diphenyl diselenide and ascorbic changes deposition of selenium and ascorbic in liver and brain of mice. Pharmacol. Toxicol. 88: 119-125.
28. Jaffe MZ. 1886. Methods determining creatinine. Physiol. Chem. 10: 39-40.
29. Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W. 2009. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol. Dial. Transplant. 24: 3012-3020.
30. Kang KP, Park SK, Kim DH, Sung MJ, Jung YJ, Lee AS, Lee JE, Ramkumar KM, Lee S, Park MH, Roh SG, Kim W. 2011. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrol. Dial. Transplant. 26: 814-822.
31. Karthikeyan K, Sarala Bai BR, Niranjali Devaraj S. 2007. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int. J. Cardiol. 115: 326-333.
32. Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W. 2000. Expression of renal aquaporins 1, 2 and 3 in rat model of cisplatin induced polyuria. Kidney Int. 58: 701-711.
33. Luchese C, Stangherlin EC, Gay BM, Nogueira CW. 2009. Antioxidant effect of diphenyl diselenide on oxidative damage induced by smoke in rats: Involvement of glutathione. Ecotoxicol. Environ. Saf. 72: 248-254.
34. Mackay EM, Mackay LL. 1927. Methods determining urea. J. Clin. Invest. 4: 295-296.
35. Misra HP, Fridovich I. 1972. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J. Biol. Chem. 247: 3170-3175.
36. Nath KA, Croatt AJ, Haggard JJ, Grande JP. 2000. Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int. 57: 2423-2433.
37. Omasu F, Oda T, Yamada M, Yoshizawa N, Yamakami K, Sakurai Y, Miura S. 2007. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am. J. Physiol. Renal Physiol. 293: 1292-1298.
38. Partibha R, Sameer R, Rataboli PV, Bhiwgade DA, Dhume CY. 2006. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur. J. Pharmacol. 532: 290-293.
39. Pereira MG, Câmara NO, Campaholle G. 2006. Pioglitazone limits cyclosporine nephrotoxicity in rats. Int. Immunopharmacol. 6: 1943-1951.
40. Quinones J, Pampaloni MH, Juarez BE. 2000. Insulin resistance in healthy Mexican Americans is associated with coronary artery endothelial dysfunction. Diabetes 49: 146.
41. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M. 1995. Oxidants in mitochondria: from physiology to diseases. Biochim. Biophys. Acta 1271: 67-74.
42. Sadzuka Y, Shimizu Y, Takino Y. 1992. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem. Pharmacol. 43: 1872-1875.
43. Shimazu T, Inoue I, Araki N. 2005. A peroxisome proliferatoractivated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36: 353.
44. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF. 2009. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol. Dial. Transplant. 24: 2384-2391.
45. Toblli JE, Cao G, Giani JF, Angerosa M, Dominici FP, Gonzales-Cadavid NF. 2011. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press. Res. 34: 20-33.
46. Ueda N, Kaushal GP, Shah SV. 2006. Apoptotic mechanisms in acute renal failure. Am. J. Med. 108: 403-415.
47. Wilhelm EA, Bortolatto CF, Nogueira CW. 2012. p-Methoxyl-diphenyl diselenide protects against cisplatin-induced renal toxicity in mice. Food Chem. Toxicol. 50: 1187-1193.
48. Wendel A. 1981. Glutathione peroxidase. Methods Enzymol. 77: 325-333.
49. Xu P, Zhou XJ, Chen LQ. 2007. Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis. World J. Gastroenterol. 13: 1983-1988.
50. Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB. 2009. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J. Am. Soc. Nephrol. 20: 2380-2388.
51. Yilmaz HR, Iraz M, Sogut S, Ozyurt ZY, Akyol O, Gergerlioglu S. 2004. The effects of erdostiene on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharmacol. Res. 50: 287-290.
52. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H. 1997. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol. 272: 989-996.
53. Zafiriou S, Stanners SR, Polhill TS, Poronnik P. 2004. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int. 65: 1647-1653.